Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

Description

Create a living biobank of PDOs from Stage I-III lung cancer patients.

Conditions

Lung Neoplasm

Talk to us

Study Overview

On this page

Study Details

Study overview

Create a living biobank of PDOs from Stage I-III lung cancer patients.

Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)

Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

Condition
Lung Neoplasm
Intervention / Treatment

-

Contacts and Locations

San Antonio

UT Health San Antonio, M.D. Anderson Cancer Center, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.
  • * Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care
  • * Any clinical stage of lung cancer
  • * Adult patients ≥18 years of age
  • * Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history
  • * At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The University of Texas Health Science Center at San Antonio,

Josephine Taverna, MD, PRINCIPAL_INVESTIGATOR, UT Health San Antonio M.D. Anderson Cancer Center

Study Record Dates

2029-12